Kathleen C. Kerrigan, DO

Journal Article

1. McCrary HC, Aoki J, Huang Y, Chadwick B, Kerrigan K, Witt B, Hunt JP, Abraham D (2022). Mutation based approaches to the treatment of anaplastic thyroid cancer. Clin Endocrinol (Oxf), 96(5), 734-742. (Read full article)
2. Fenlon JB, Hutten RJ, Weil CR, Lloyd S, Cannon DM, Kerrigan K, Cannon RB, Hitchcock YJ (2021). Comparing adjuvant radiation to adjuvant chemoradiation in postsurgical p16+ oropharyngeal carcinoma patients with extranodal extension or positive margins. Head Neck, 44(3), 606-614. (Read full article)
3. Wang X, Kerrigan K, Puri S, Shen J, Akerley W, Haaland B (2022). Dynamic Prediction of Near-Term Overall Survival in Patients with Advanced NSCLC Based on Real-World Data. Cancers (Basel), 14(3). (Read full article)
4. Stetson PD, McCleary NJ, Osterman T, Ramchandran K, Tevaarwerk A, Wong T, Sugalski JM, Akerley W, Mercurio A, Zachariah FJ, Yamzon J, Stillman RC, Gabriel PE, Heinrichs T, Kerrigan K, Patel SB, Gilbert SM, Weiss E (2022). Adoption of Patient-Generated Health Data in Oncology: A Report From the NCCN EHR Oncology Advisory Group. J Natl Compr Canc Netw, 1-6. (Read full article)
5. Kerrigan K, Jo Y, Chipman J, Haaland B, Puri S, Akerley W, Patel S (2022). A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern. JTO Clin Res Rep, 3(3), 100280. (Read full article)
6. Kerrigan K, Chan J, Vagher J, Kohlmann W, Naumer A, Anson J, Low S, Schiffman J, Maese L (2021). Lung Cancer in Li Fraumeni Syndrome. . JCO Precis Oncol, 23(5).
7. Kerrigan K, Wang X, Haaland B, Adamson B, Patel S, Puri S, Akerley W (2021). Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status. Clin Lung Cancer.
8. Kerrigan K, Patel SB, Haaland B, Ose D, Chalmers AW, Haydell T, Meropol NJ, Akerley WL (2020). Prognostic Significance of Patient-Reported Outcomes in Cancer. 16(4), 313-323.
9. Kerrigan K, Shoben A, Otterson G (2016). Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit. Clin Lung Cancer, 17(6), 523-527. (Read full article)
10. Kerrigan KOtterson G (2016). Evaluation of the Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients with Actionable Mutations Treated with Molecular Targeted Therapy in the Intensive Care Unit Setting. Am J Respir Crit Care Med.

Review

1. Kerrigan K, Puri S (2022). Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer. [Review]. Curr Oncol Rep, 24(1), 113-123. (Read full article)
2. Naqash AR, Kihn-Alarcon AJ, Stavraka C, Kerrigan K, Vareki M, Pinato DJ, Puri S (2021). The Role of Gut Microbiome in Modulating Response to Immune Checkpoint Inhibitor Therapy in Cancer. [Review]. Ann Transl Med.

Case Report

1. Johnson ED, Kerrigan K, Butler K, Patel SB (2019). Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy. J Oncol Pharm Pract, 26(1), 224-227. (Read full article)
2. Griswold CR, Kerrigan K, Patel SB (2019). Combination of Local Ablative Therapy and Continuation of Immune Checkpoint Inhibitor (ICI) Therapy Provides Durable Treatment Response Past Oligometastatic Progression in NSCLC: A Case Report. Case Rep Oncol, 12(3), 866-871. (Read full article)

Abstract

1. Owonikok TK, Elliot A, Dwivedi B, Ivanov A, Sica G, Kerrigan K, et al (2022). Surfaceome profiling to reveal unique therapeutic vulnerabilities in transcriptional subtypes of small cell lung cancer (SCLC) [Abstract].
2. Russell J, Kerrigan K, Yang D (2022). Circulating tumor DNA profiling and serial analysis in salivary gland carcinomas reveal unique mutational subsets and actionable alterations [Abstract].
3. Kerrigan K, Puri S, Sinnott JHaaland B, Akerley W, Patel SB (2021). Management of Patients with EGFR and ALK-Mutated Advanced Non-Small Cell Lung Cancer Post-TKI Therapy – A Real-World Survival Analysis. [Abstract]. 16(3), 89.05.
4. Kerrigan K, Chipman J, Jo Y, Haaland B, Johnson E, Puri S, Varghese T, Akerley W, Patel SB (2021). Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Physician’s Choice of First-line Platinum Chemotherapy. [Abstract]. 16(3 S122-123), OA09.05.
5. Kerrigan K, Chipman J, Jo Y, Haaland B, Johnson E, Puri S, Varghese T, Akerley W, Patel SB (2021). Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Choice of Second-line Therapy. [Abstract]. 16(3, S199), FP05.01.
6. Puri S, Patel S, Chalmers A, Kerrigan K, Cannon L, George S, Boucher K, Akerley W (2021). Phase Ib Study to Evaluate the Safety and Efficacy of Osimertinib in Combination with Ipilimumab in EGFR Mutated NSCLC [Abstract]. 16(3, S344), P15.02.
7. Kerrigan K, Haaland B, Adamson B, Patel S, Akerley W (2019). Real-World Survival of Relapsed Compared to De-Novo Stage IV Diagnosis of Advanced Non-Small Cell Lung Cancer   [Abstract]. 14(10), S307-308.
8. Kerrigan K, Haaland B, Adamson B, Patel S, Akerley W (2019). Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers   [Abstract]. 14(10), P1.01-35.

Video/Film/CD/Web/Podcast

1. Kerrigan K (2019). Incorporation PROs Can Improve Patient Care and Outcomes [Web]. OncLive Oncology Fellows Magazine.

• Phase II Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer
• Phase II Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer
• Phase III, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared with Investigator?s Choice Monotherapy Treatment in Previously Treated Patients with Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma
• A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)
• Phase IB/II, Open-Label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
• Phase IB/II, Open-Label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
• Phase IB/II, Open-Label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
• Phase IB/II, Open-Label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
• Phase IB/II, Open-Label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
• Phase IB/II, Open-Label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
• Phase IB/II, Open-Label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
• Phase I/II Study of Nivolumab and Ipilimumab in Combination with Sirolimus and Prednisone in Kidney Transplant Recipients with Selected Unresectable or Metastatic Cutaneous Cancers
• Phase III Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-Line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma